SAN RAFAEL, Calif., Nov. 19, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today …
BioMarin
European Commission Approves BioMarin’s VOXZOGO® (vosoritide) for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
Achondroplasia is the Most Common Cause of Dwarfism First Medicine Approved to Treat Children with Achondroplasia in …
Vosoritide in Europe: will payers cover BioMarin’s dwarfism drug?
via Clinical Trials Arena by William Newton. Vosoritide’s uncertain long-term efficacy may limit European coverage of …
BioMarin gears up for two ‘transformational’ launches, Voxzogo and Roctavian: CEO
Source – Fierce Pharma. While BioMarin bested expectations with its second-quarter performance, the biotech is zeroed in …
BioMarin Receives Positive CHMP Opinion in Europe for Vosoritide for the Treatment of Children with Achondroplasia from Age 2 Until Growth Plates Close
European Commission Decision expected Q3 2021Temporary Authorization for Use (ATU) Granted in France to Allow Access and …
Novel therapy improves height for children with achondroplasia
via Healio/Endocrine Today Children with a common form of skeletal dysplasia saw persistent and sustained …